MIR3174: A Potential Drug Target and Biomarker (G100422841)
MIR3174: A Potential Drug Target and Biomarker
Molecular Intelligence (MIT) has identified a potential drug target and biomarker for the treatment of various diseases, including cancer, neurodegenerative diseases, and metabolic disorders. The target is MIR3174, a protein that is expressed in various tissues and cells throughout the body. In this article, we will explore the biology of MIR3174, its potential as a drug target, and its potential as a biomarker for disease diagnosis and treatment.
The MIR3174 Protein
MIR3174 is a 21-kDa protein that is expressed in various tissues and cells throughout the body, including the brain, heart, liver, and muscle. It is a member of the serine/threonine protein kinase (STK) family and is involved in various cellular processes, including cell signaling, DNA replication, and cell survival. MIR3174 has been shown to play a role in the regulation of cell proliferation, differentiation, and survival.
MIR3174 has also been shown to be involved in the regulation of various signaling pathways, including the PI3K/Akt signaling pathway, the TGF-β signaling pathway, and the NF-kappa-B signaling pathway. MIR3174 has been shown to play a negative role in these signaling pathways, which may contribute to its potential as a drug target.
MIR3174 as a Drug Target
MIR3174 has been shown to be a potential drug target for a variety of diseases, including cancer, neurodegenerative diseases, and metabolic disorders.
In cancer, MIR3174 has been shown to play a negative role in the regulation of cell growth and survival. For example, MIR3174 has been shown to inhibit the effects of the anti-cancer drug doxorubicin by preventing its binding to the DNA-protein complex, which is critical for cell growth and survival.
In neurodegenerative diseases, MIR3174 has been shown to play a role in the regulation of neurotransmitter signaling and cell survival. For example, MIR3174 has been shown to regulate the levels of neurotransmitters, such as dopamine and serotonin, in the brain and to play a role in the survival of neurotransmitter-dependent neurons.
In metabolic disorders, MIR3174 has been shown to play a role in the regulation of insulin sensitivity and glucose metabolism. For example, MIR3174 has been shown to regulate the activity of the GLUT4 protein, which is involved in insulin sensitivity and glucose metabolism.
MIR3174 as a Biomarker
MIR3174 has also been shown to be a potential biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and metabolic disorders.
In cancer, MIR3174 has been shown to be a potential biomarker for the development and progression of various types of cancer, including breast, ovarian, and colorectal cancers. This is because MIR3174 has been shown to play a negative role in the regulation of cell growth and survival, which may contribute to its potential as a drug target or biomarker for cancer.
In neurodegenerative diseases, MIR3174 has been shown to be a potential biomarker for the progression of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. This is because MIR3174 has been shown to play a role in the regulation of neurotransmitter signaling and cell survival, which may contribute to its potential as a drug target or biomarker for neurodegenerative diseases.
In metabolic disorders, MIR3174 has been shown to be a potential biomarker for the diagnosis and treatment of various metabolic disorders, including type
Protein Name: MicroRNA 3174
The "MIR3174 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR3174 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
MIR3175 | MIR3176 | MIR3177 | MIR3178 | MIR3179-1 | MIR3179-2 | MIR3179-3 | MIR3180-1 | MIR3180-2 | MIR3180-3 | MIR3180-4 | MIR3180-5 | MIR3182 | MIR3183 | MIR3184 | MIR3185 | MIR3186 | MIR3187 | MIR3188 | MIR3189 | MIR3190 | MIR3191 | MIR3192 | MIR3193 | MIR3194 | MIR3195 | MIR3196 | MIR3197 | MIR3198-1 | MIR3199-1 | MIR3199-2 | MIR31HG | MIR32 | MIR3200 | MIR3201 | MIR3202-1 | MIR3202-2 | MIR320A | MIR320B1 | MIR320B2 | MIR320C1 | MIR320C2 | MIR320D1 | MIR320D2 | MIR320E | MIR323A | MIR323B | MIR324 | MIR325 | MIR325HG | MIR326 | MIR328 | MIR329-1 | MIR329-2 | MIR330 | MIR331 | MIR335 | MIR337 | MIR338 | MIR339 | MIR33A | MIR33B | MIR340 | MIR342 | MIR345 | MIR346 | MIR34A | MIR34AHG | MIR34B | MIR34C | MIR3529 | MIR3591 | MIR3605 | MIR3606 | MIR3609 | MIR361 | MIR3610 | MIR3611 | MIR3612 | MIR3613 | MIR3614 | MIR3615 | MIR3616 | MIR3617 | MIR3618 | MIR3619 | MIR362 | MIR3620 | MIR3621 | MIR3622A | MIR3622B | MIR363 | MIR3646 | MIR3648-1 | MIR3649 | MIR3650 | MIR3651 | MIR3652 | MIR3654 | MIR3655
